S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.88 (+0.87%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.08 (+1.41%)
GOOGL   2,865.54 (+0.35%)
TSLA   866.00 (-0.47%)
AMZN   3,442.28 (-0.13%)
NVDA   223.19 (+0.44%)
BABA   177.01 (+6.11%)
NIO   39.94 (+0.83%)
CGC   14.38 (+8.94%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.66 (+0.59%)
T   25.56 (+0.91%)
F   15.43 (-0.84%)
ACB   7.45 (+7.66%)
DIS   171.24 (+0.06%)
PFE   42.05 (+1.77%)
BA   215.81 (-0.54%)
AMC   40.45 (-6.00%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.88 (+0.87%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.08 (+1.41%)
GOOGL   2,865.54 (+0.35%)
TSLA   866.00 (-0.47%)
AMZN   3,442.28 (-0.13%)
NVDA   223.19 (+0.44%)
BABA   177.01 (+6.11%)
NIO   39.94 (+0.83%)
CGC   14.38 (+8.94%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.66 (+0.59%)
T   25.56 (+0.91%)
F   15.43 (-0.84%)
ACB   7.45 (+7.66%)
DIS   171.24 (+0.06%)
PFE   42.05 (+1.77%)
BA   215.81 (-0.54%)
AMC   40.45 (-6.00%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.88 (+0.87%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.08 (+1.41%)
GOOGL   2,865.54 (+0.35%)
TSLA   866.00 (-0.47%)
AMZN   3,442.28 (-0.13%)
NVDA   223.19 (+0.44%)
BABA   177.01 (+6.11%)
NIO   39.94 (+0.83%)
CGC   14.38 (+8.94%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.66 (+0.59%)
T   25.56 (+0.91%)
F   15.43 (-0.84%)
ACB   7.45 (+7.66%)
DIS   171.24 (+0.06%)
PFE   42.05 (+1.77%)
BA   215.81 (-0.54%)
AMC   40.45 (-6.00%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.88 (+0.87%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.08 (+1.41%)
GOOGL   2,865.54 (+0.35%)
TSLA   866.00 (-0.47%)
AMZN   3,442.28 (-0.13%)
NVDA   223.19 (+0.44%)
BABA   177.01 (+6.11%)
NIO   39.94 (+0.83%)
CGC   14.38 (+8.94%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.66 (+0.59%)
T   25.56 (+0.91%)
F   15.43 (-0.84%)
ACB   7.45 (+7.66%)
DIS   171.24 (+0.06%)
PFE   42.05 (+1.77%)
BA   215.81 (-0.54%)
AMC   40.45 (-6.00%)
NASDAQ:BEAM

Beam Therapeutics Price Target, Predictions & Analyst Ratings

$94.35
+3.64 (+4.01 %)
(As of 10/19/2021 03:59 PM ET)
Add
Compare
Today's Range
$91.47
$96.30
50-Day Range
$83.00
$114.07
52-Week Range
$29.43
$138.52
Volume16,202 shs
Average Volume891,290 shs
Market Capitalization$6.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Beam Therapeutics (NASDAQ:BEAM) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 9 Analyst Ratings

Analyst Price Target Consensus

$119.50

High PT$150.00
Average PT$119.50
Low PT$85.00
TypeCurrent
10/19/20 to 10/19/21
1 Month Ago
9/19/20 to 9/19/21
3 Months Ago
7/21/20 to 7/21/21
1 Year Ago
10/20/19 to 10/19/20
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$119.50$119.83$100.33$33.60
Price Target Upside26.66% Upside25.98% Upside16.92% Upside36.42% Upside
Get Beam Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Beam Therapeutics (NASDAQ:BEAM) vs. Its Competitors

TypeBeam TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.72
2.56
Consensus RatingBuyBuyBuy
Price Target Upside144.24% Upside7.59% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
16
50.00%
Underperform Votes
16
50.00%
Avg. Outperform Votes
178
67.42%
Avg. Underperform Votes
86
32.58%
Avg. Outperform Votes
830
69.46%
Avg. Underperform Votes
365
30.54%

Beam Therapeutics (NASDAQ:BEAM) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/19/2021SVB Leerink
Initiated CoverageOutperform$117.00+28.98%
9/24/2021Stifel Nicolaus
Initiated CoverageBuy$85.00 ➝ $120.00+24.20%
9/10/2021Bank of America
Initiated CoverageBuy$150.00+37.35%
6/29/2021Wedbush
Boost Price TargetOutperform$114.00 ➝ $149.00+36.89%
5/11/2021Redburn Partners
Initiated CoverageBuy
5/3/2021Royal Bank of Canada
Initiated CoverageSector Perform$85.00+13.05%
3/8/2021Barclays
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $90.00+23.97%
2/16/2021Wells Fargo & Company
Initiated CoverageOverweight$145.00+38.10%
1/29/2021JPMorgan Chase & Co.
DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00+0.11%
8/12/2020William Blair
Raju Prasad
Initiated CoverageBuy
3/2/2020Jefferies Financial Group
Initiated CoverageBuy$32.00+42.29%
(Data available from 10/19/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Beam Therapeutics (NASDAQ:BEAM) Analyst Ratings Frequently Asked Questions

What is Beam Therapeutics's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Beam Therapeutics stock is Buy based on the current 3 hold ratings and 6 buy ratings for BEAM. The average twelve-month price target for Beam Therapeutics is $119.50 with a high price target of $150.00 and a low price target of $85.00. Learn more on BEAM's analyst rating history

Do Wall Street analysts like Beam Therapeutics more than its competitors?

Analysts like Beam Therapeutics stock less than the stock of other Medical companies. The consensus rating score for Beam Therapeutics is 2.67 while the average consensus rating score for medical companies is 2.72. Learn more on how BEAM compares to other companies

Do MarketBeat users like Beam Therapeutics more than its competitors?

MarketBeat users like Beam Therapeutics stock less than the stock of other Medical companies. 50.00% of MarketBeat users gave Beam Therapeutics an outperform vote while medical companies recieve an average of 67.42% outperform votes by MarketBeat users.

Does Beam Therapeutics's stock price have much upside?

According to analysts, Beam Therapeutics's stock has a predicted upside of 26.11% based on their 12-month price targets.

What analysts cover Beam Therapeutics?

Beam Therapeutics has been rated by Bank of America, Stifel Nicolaus, and SVB Leerink in the past 90 days.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.